Positive Patient Stories™

Paratek Pharmaceuticals News

Webcast ImageWebcast
Fourth Quarter and Fiscal Year 2018 Earnings Call  (Replay)
02/27/19 at 4:30 p.m. ET
Fourth Quarter and Fiscal Year 2018 Earnings Call
Wednesday, February 27, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
8th Annual SVB Leerink Global Healthcare Conference (Replay)
02/28/19 at 1:00 p.m. ET
8th Annual SVB Leerink Global Healthcare Conference
Thursday, February 28, 2019 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Paratek Pharmaceuticals Presentation at the Cowen and Company 39th Annual Health Care Conference (Replay)
03/13/19 at 10:00 a.m. ET
Paratek Pharmaceuticals Presentation at the Cowen and Company 39th Annual Health Care Conference
Wednesday, March 13, 2019 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle  
12/20/17FDA Accepts New Drug Application for Seysara™ (Sarecycline) for the Treatment of Moderate to Severe Acne 
12/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
11/08/17Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018 
11/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
10/24/17Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017 
10/06/17Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria 
10/06/17Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions 
10/02/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
09/25/17Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 
09/21/17Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections 
09/19/17Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017 
09/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
08/22/17Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences 
08/08/17Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference 
08/02/17Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update 
08/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
07/19/17Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017 
07/17/17Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections 
07/07/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
06/14/17Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference 
06/03/17New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections 
05/24/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017 
05/08/17Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July 
05/04/17Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update 
04/26/17Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017 
04/25/17Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data 
04/24/17Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China 
04/24/17New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections 
04/24/17New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA 
04/18/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017 
04/03/17Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia 
03/27/17Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne 
03/24/17Paratek Pharmaceuticals Opens New Office in King of Prussia 
03/02/17Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 
02/22/17Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 
02/08/17Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference 
01/18/17Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study 
01/04/17Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.